In fact, the similarities were greater than those observed between the CML LSCs (CD34+CD38−ALDHhigh cells) and the CML progenitors (CD34+CD38+ cells), underpinning the challenge in selectively targeting LSCs without injuring normal HSCs. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.